Dec 09,2024

Study Confirms AI Test PreciseBreast Matches Oncotype DX in Predicting Breast Cancer Recurrence

COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida announced new study results validating the artificial intelligence (AI)-enabled PreciseBreast™ test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. Presented at the San Antonio Breast Cancer Symposium, the test integrates demographic, pathology, and biomarker data to assess recurrence risk. With comparable accuracy, faster results (48 hours vs. weeks), and lower cost (20% of Oncotype DX), PreciseBreast offers an accessible and efficient alternative for optimizing breast cancer diagnostics and treatment pathways. This innovation highlights the transformative potential of AI in oncology care.

#rwe

View Analyst & Ambassador Comments
Go to original news
Apr 08,2024

Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2- Directed Antibody-Drug Conjugates in Several Tumor Types

Tempus collaborates with Pfizer to present new data at the AACR 2024 Annual Meeting. The study explores HER2 expression across various solid tumors, indicating potential therapeutic routes for HER2-directed antibody-drug conjugates beyond breast and gastric cancers. By correlating HER2 protein and ERBB2 mRNA levels, the research suggests opportunities for targeted therapies. Tempus' computational and real-world evidence teams support Pfizer's research efforts, leveraging their multimodal database to analyze patient cohorts and provide insights into HER2 expression in solid tumors.

COLLABORATION PARTNERSHIP

#r&d

#rwe

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 04,2024

Medisafe Launches Real-World “Data Pulse” Packages to Support Partners’ Brand Strategy and Revenue Growth

Medisafe, an industry-leading digital health company specializing in medication management, is pleased to introduce ‘Data Pulse,’ a new data package offering, that will enable partners to inform their user experience strategy by leveraging real-world, real-time insights derived from aggregated, de-identified, HIPAA- and GDPR-compliant user data. With insights based on over 30 billion behavioral data points collected through interactions with 90+ health trackers, partners will be able to understand insights on users’ needs and habits, aid in the development of personalized medicine and treatment plans, generate real-world data evidence for market access, demand forecasting and identify gaps in treatment adherence to develop targeted user support programs. The offering is scalable and includes customizable surveys, aimed at generating primary research for user insights, segmentation analysis, competitive analysis, and condition analysis for commercialization.

PRODUCT

#rwe

View Analyst & Ambassador Comments
Go to original news
Nov 15,2023 TOP STORY

COTA and Aetion partner to expand access to real-world data for oncology research

COTA has partnered with Aetion®, a global leader in real-world evidence (RWE) and analytics, to make it faster and easier to access fit-for-purpose datasets for research. By combining the power of the Aetion Evidence Platform® (AEP) with COTA’s clinically curated, multi-source oncology Vantage RWD assets, investigators will be able to streamline access to meaningful data so they can focus on the science instead. This collaboration enables Aetion and COTA to meet the needs of researchers requiring high-quality, clinically rich oncology data, for both liquid and solid tumor types.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Sep 06,2023

Flatiron Health enters new five-year research collaboration with FDA on real-world data

Flatiron Health today announced its renewed collaboration with the Oncology Center of Excellence (OCE) of the United States Food and Drug Administration (FDA) to jointly develop and implement specific research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. The partnership will specifically evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

Enriching access to multimodal data insights with COTA Connect

COTA is introducing COTA Connect: a powerful new capability to link data with a variety of different supplemental data sources, including linking COTA’s robust real-world clinical data to claims, imaging, socioeconomic data, and more. COTA will provide the tokens that allow linkage to a claims data source, creating a more comprehensive view of patients’ care. This increases granularity of understanding around individuals and populations of interest. According to the press release, COTA can also provide analytical services to analyze the merged dataset and answer relevant research questions.

PRODUCT

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jul 07,2023

European Real-World Evidence and Data Analytics Conference 2023: Revolutionizing Healthcare with RWD / RWE to Accelerate Regulatory Decision Making

The "Real-World Evidence and Data Analytics Conference" will take place in Frankfurt, Germany on October 5-6, 2023. The event will focus on using real-world data and evidence to accelerate regulatory decision making in healthcare. Topics will include RWE in rare diseases, data quality, AI & ML in clinical trials, and more. Pharmaceutical and biopharmaceutical professionals involved in real-world evidence, data analytics, health economics, clinical development, and other related fields are encouraged to attend.

CONFERENCES

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 08,2023

COTA-Powered Research will be Presented at the Annual Congress of the European Hematology Association

The fruits of COTA’s expanded research and consulting services — Real-World Insights and Real-World Support — will be on display at the annual Congress of the European Hematology Association (EHA) being held in Frankfurt and online June 8-11. DLBCL is the most common subtype of non-Hodgkin lymphoma. Standard of care for frontline therapy remains chemoimmunotherapy; however, nearly half of the patients will experience relapse or refractory (R/R) disease. A research team from COTA and Merck Sharp & Dohme, a subsidiary of Merck & Co., analyzed RWD from 1347 eligible patients, the majority of whom (81.3%) received treatment in the community practice setting. The study concludes that there is a significant need for improved therapy options for patients who do not respond to the current initial standard of care.

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
May 17,2023

Flatiron adds service with 'data empathy' for oncology trials

Flatiron Health debuted its latest offering of its real-world evidence (RWE) platform to include data and end-to-end services focused on growing needs in the arena of oncology clinical trials. The additions by Flatiron provide a one-stop-shop for oncology real-world data by giving customers more flexibility in the way they engage with the platform to deliver oncology evidence solutions tailored to their particular needs, the company said in a May 15 press release.

PRODUCT

#rwe

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 25,2023

PathAI and ConcertAI Partner to Create First-in-class Histopathology and Curated Clinical Real-World Data Product

PathAI, a global leader in AI-powered pathology, and ConcertAI, a leader in AI software-as-a-service (SaaS) technology and real-world evidence (RWE) solutions for life sciences and healthcare, today announced a strategic partnership to launch a first-in-class quantitative histopathology and curated clinical real-world data (RWD) solution combining PathAI’s PathExplore™ tumor microenvironment panel with ConcertAI’s Patient360™ and RWD360™ products. Utilizing real world H&E-stained samples from PathAI’s pathology laboratory, PathExplore extracts quantitative measures of the tumor microenvironment, known as human interpretable features (HIFs), from whole slide images. These data are linked to Patient360’s reference-standard abstracted clinical EMR, medical claims, and Social Determinants of Health data, allowing direct insights into current standards of care and treatment dynamics. ConcertAI and PathAI will jointly offer these combined solutions to biopharma customers, including translational research and real-world data teams. The initial solutions focus on bladder cancer, colorectal cancer, prostate cancer, and melanoma.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWE